INI-4001
Asset
Activates TLR7 and TLR8 to stimulate cytokine production and antitumor immune responses.
- Stage
- Phase 1
- Modality
- Small molecule
- Target
- TLR7
- 1
- Indication
- 1
- Trial
- 1
- Developer
Named in the news on Nov 6, 2026. prnewswire.com
Indications
1Advanced solid tumor
Phase 1, Completed, NCT06302426, clinicaltrials.gov, Nov 11, 2026
In the full profile
- Target and mechanism1
- Owner and partners1
- Trials1
- Evidence for its targets2
- Competitors12
- Signals2
Every asset’s record: target, stage, trials and the evidence behind it.